Answers are grounded in this paper and cite their sources.
Probability of treatment-free remission (TFR) in CML patients with additional chromosomal abnormalities (ACA) in the Philadelphia-positive clone or variant Philadelphia translocations (ACA/Var-Ph group, blue panel), in those with no cytogenetic abnormality other than the classical Philadelphia translocation (c-Ph group, green panel) and in the subgroups of CML patients with high-risk ACA (HR-ACA, yellow panel) and Var-Ph (red panel).
No takes yet. Share an insight, caveat, or question.
Claudiani et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: